In this report we describe the molecular basis of the factor IX (FIX) deficiency in nine patients with severe (n = 6), moderate (n = 1) or mild (n = 2) hemophilia B. The following genetic defects were identified by enzymatic amplification with the polymerase chain reaction (PCR) and subsequent direct sequencing of all exons and exon-intron-junctions: patient B.B. (FIX “Vienna I”): deletion of nucleotides 6343 to 6362; patient M.H. and W. J. (FIX “Vienna II”): nucleotide 17704 (C to G), Gin 97 to Glu; patient L. K. (FIX “Vienna III”): nucleotide 17761 (C to T), Arg 116 to stop; patient U. A. (FIX “Vienna IV”): nucleotide 10415 (C to G), Pro 55 to Ala; patient H.G. (FIX “Vienna V”): nucleotide 6488 (C to T), Thr 38 to lie; patient H. M. (FIX “Vienna VI”): nucleotide 31276 (G to C), Trp 385 to Cys; patient L. C. (FIX “Vienna VII”): deletion of nucleotide 6700; patient S.F. (FIX “Vienna VIII”): nucleotide 10392 (A to T), Asp 47 to Val. The causative mutation was detected in the FIX gene in each of the nine patients with hemophilia B. There was one small deletion, one point deletion and seven point mutations. The latter include six missense mutations and one nonsense mutation. The mutations in Vienna III, IV and V have already been described in previous studies. The two deletions, Vienna I and Vienna VII have not been reported previously. The genetic defects observed in Vienna II, VI and VIII are novel missense mutations which result in amino acid changes at residues 97,47 and 385, respectively.
References
1
Camerino G,
Grzeschik KH,
Jaye M,
De La Salle H,
Tolstoshev P,
Lecocq JP,
Heilig R,
Mandel JL.
Regional localization on the human X chromosome and polymorphisms of the coagulation factor IX gene. Proc Natl Acad Sci USA 1984; 81: 498
3
Yoshitake S,
Schach BG,
Foster DC,
Davie EW,
Kurachi K.
Nucleotide sequence of the gene for human factor IX (antihemophilic factor IX). Biochemistry 1985; 24: 3736-3750
5
Jorgensen MJ,
Cantor AB,
Furie BC,
Brown CL,
Shoemaker CB,
Furie B.
Recognition site directing gamma-carboxylation resides on the propeptide of factor IX. Cell 1987; 48: 185-191
6
Me Mullen BA,
Fujikawa K,
Kisiel W.
The occurrence of the beta-hydroxyaspartic acid in the vitamin K-dependent blood coagulation zymogens. Biochem Biophys Res Commun 1983; 115: 8
7
Hassan HJ,
Leonardi A,
Guerriero R,
Chelucci C,
Cianetti L,
Ciavarella N,
Ranieri P,
Pilolli D,
Peschle C.
Hemophilia B with inhibitor; molecular analysis of the subtotal deletion of the factor IX gene. Blood 1985; 66: 728
8
Chen SH,
Yoshitake S,
Chance PF,
Bray GL,
Thompson AR,
Scott CR,
Kurachi K.
An intragenic deletion of the factor IX gene in a family with hemophilia B. J Clin Invest 1985; 76: 2161
9
Taylor SAM,
Lillicrap DP,
Blanchatte V,
Giles AR,
Holden JJA,
White BN.
A complete deletion of the factor I gene and new Taq 1 variant in a hemophilia B kindred. Hum Genet 1988; 79: 273
11
Huang MN,
Kasper CK,
Roberts HR,
Stafford DW,
High KA.
Molecular defect in factor IX “Hilo”, a hemophilia Bm variant: Arg → Gin at the car-boxyterminal cleavage site of the activation peptide. Blood 1989; 73: 718
12
Denton PH,
Fowlkes DM,
Lord ST,
Reisner HM.
Hemophilia B Durham: A mutation in the first EGF-like domain of factor IX that is characterized by polymerase chain reaction. Blood 1988; 72: 1407
13
Davis LM,
McGraw RA,
Ware JL,
Roberts HR,
Stafford DW.
Factor IX Alabama: A point mutation in a clotting protein results in hemophilia B. Blood 1987; 69: 140
14
Winship PR,
Rees DJG,
Alkan M.
Detection of polymorphisms at cytosine phosphoguanadine dinucleotides and diagnosis of hemophilia B carriers. Lancet 1989; i: 631
18
Saiki RK,
Gelfand DH,
Stoffel S,
Scharf SJ,
Higuchi RG,
Horn TT,
Mullis KB,
Erlich HA.
Primer-directed enzymatic amplification of DNA with a thermostable DNA Polymerase. Science 1988; 239: 487-491
19
Watzke HH,
Lechner K,
Roberts HR,
Sakamuri RV,
Welsch DJ,
Friedman P,
Mahr G,
Monroe DM,
High KA.
Molecular defect (Gla 14-Lys) and its functional consequences in a hereditary factor X deficiency. J Biol Chem 1989; 265: 11982-11989
21
Montandon AJ,
Green PM,
Bentley DR,
Ljung R,
Nilsson IM,
Gianelli F.
Two factor IX mutations in the family of an isolated haemophilia B patient: direct carrier diagnosis by amplification mismatch detection (AMD). Hum Gen 1990; 85: 200-204
22
Spitzer SG,
Kuppuswamy MN,
Saini R,
Kasper CK,
Birktoft JJ,
Bajaj SP.
Factor IX “Hollywood”. Substitution of Pro 55 by Ala in the first epidermal growth factor-like domain. Blood 1990; 76: 1530-1537
23
Gianelli F,
Green PM,
High KA,
Poon MC,
Ludwig M,
Schwaab R,
Reitsma PH,
Goossens M,
Yoshioka A,
Brownlee GG.
Haemophilia B: database of point mutations and short additions and deletions - fourth edition, 1993. Nucl Acid Res 1993; 21: 3075-3087
24
Morita T,
Isaacs BS,
Esmon CT,
Johnson AE.
Derivatives of blood coagulation factor I contain a high affinity Ca2+-binding site that lacks gamma-carboxyglutamic acid.. J Biol Chem 1984; 259: 5698
25
Me Cord DM,
Monroe DM,
Roberts HR.
Characterization of the functional defect in factor IX “Alabama”. A mutation near the first EGF-like domain results in defective interaction with factor Villa. Blood 1988; 72: 302a (abstr).
26
Bottema CDK,
Ketterling RP,
Setsuko LI,
Yoon HS,
Phillips III JA,
Sommer SS.
Missense mutations and evolutionary conservation of amino acids: Evidence that many of the amino acids in factor IX function as “Spacer” elements. Am J Hum Genet 1991; 49: 820-838
29
Bertina RM,
van der Linden IK,
Mannucci PM,
Reinalda-Poot HH,
Cupers R,
Poort SR,
Reitsma PH.
Mutations in hemophilia Bm occur at the Arg 180-Val activation site or in the catalytic domain of factor IX. J Biol Chem 1990; 265: 10876-10883
